33 min listen
Rational Use of New and Emerging Agents for Hepatitis Delta Virus
Rational Use of New and Emerging Agents for Hepatitis Delta Virus
ratings:
Length:
21 minutes
Released:
Mar 16, 2022
Format:
Podcast episode
Description
Hepatitis delta virus (HDV) is the most severe form of viral hepatitis and warrants new treatment options for better efficacy and tolerability. In part 2 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on new and emerging treatment options for HDV and rational use of these new agents. Their discussion includes:Assembly inhibitors (eg, lonafarnib)Entry inhibitors (eg, bulevirtide)Interferon lambdaNucleic acid polymersSmall interfering RNA (siRNA) agentsPresenters: Heiner Wedemeyer, MDProfessor and ChairmanDepartment of Gastroenterology, Hepatology, and EndocrinologyHannover Medical SchoolHannover, GermanyCihan Yurdadin, MDProfessor and Chief Department of Gastroenterology and HepatologyKoç University Medical SchoolIstanbul, TurkeyLink to full program:https://bit.ly/365VUlG
Released:
Mar 16, 2022
Format:
Podcast episode
Titles in the series (100)
COVID-19: Answering the Questions, Part 5: In Part 5 of this ongoing 12-part COVID-19 series, listen to a brief update on the epidemiology of SARS-CoV-2 and evidence-based interventions for reducing transmission, followed by answers to critical clinician questions on COVID-19 transmission and mitigation by David Heymann, BA, MD, DTM&H. by CCO Infectious Disease Podcast